Alzheimer’s vaccine clears amyloid plaques but has small effect on learning and memory impairment A promising vaccine being tested for Alzheimer’s disease does what it is designed to do – – obvious beta-amyloid plaques from the brain – – but it does not appear to help restore dropped learning and storage abilities, according to a University of California, Irvine study. The findings suggest that treating the predominant pathology of Alzheimer’s disease – – beta-amyloid plaques – – alone may have just limited clinical advantage if started after there is significant plaque growth proventil therapeutic class click here . However, a combination of vaccination with therapies that also focus on related neuron damage and cognitive decline might provide the best treatment opportunity for people with this neurodegenerative disease. Study results come in the April 2 issue of the Journal of Neuroscience. Related StoriesNew vaccine is apparently more effective in reducing 'bad' LDL cholesterolResearchers reveal why malaria vaccine provides only moderate protection among vaccinated childrenBasic analysis for developing toxoplasma vaccine underway’We’ve found that reducing plaques is only area of the puzzle to treat Alzheimer disease,’ said research head, UC Irvine neurobiologist Elizabeth Head. ‘Vaccines such as this one are a good first step for effective Alzheimer’s treatment, but complimentary treatments should be developed to handle the complexity of the condition.’ Head and colleagues studied for a two-12 months period in ageing canines the effect of a vaccine that’s currently under clinical development for treating patients with Alzheimer’s disease. The vaccine contains the beta-amyloid 1-42 protein and stimulates the immune system to produce antibodies against this same protein that is in the brain plaques. Dogs are used for such research because beta-amyloid plaques grow normally in their brains and they exhibit cognitive declines equivalent to those seen in humans. After the aged dogs with beta-amyloid-plaque growth were immunized , the experts found, in comparison with non-treated aged dogs, little difference in the full total results of behavioral tests that measure cognitive reduction. Later, brain autopsies showed that although plaques have been cleared from multiple brain regions – – including the entorhinal cortex, an area of the brain associated with learning and storage and primarily affected by Alzheimer’s – – broken neurons remained. Mind said this discovery assists explain why there is little difference in the behavioral test results between immunized and nonimmunized canines. In addition, she added, it means that after clearing beta-amyloid plaques from the brain, the next step is to correct these neurons. This approach will be critical for treating and reversing the effects of the Alzheimer’s disease. Currently, Head and her colleagues are developing methods to repair these broken neurons and hope to test them clinically. The Ambry XLMR SuperPANEL spans all degrees of genetic resolution, from genome-wide scan through focused study of the X chromosome to base-pair analysis of around ninety specific target genes. ‘The brand new technologies create a significant paradigm shift and allow us to comprehensively investigate complex genetic disorders just as monogenic disorders have been diagnosed for years.’ ‘Ambry Genetics is preferably suitable for bring multigenic assays into the marketplace,’ said Charles Dunlop, Chief Executive Officer.’.

generic equivalent